<ѻý>Hospitalizations After Fake Ozempic; Abortion Rights Win Big; Ketamine Use Boomsѻý> Health news and commentary from around the Web gathered by ѻý staff Nov 08, 2023
<ѻý>Kidney Week Roundup: Cell Therapy Cuts Immunosuppressive Drug Use Post-Transplantѻý> Plus: bardoxolone methyl for diabetic kidney disease and spironolactone in hemodialysis patients Nov 07, 2023
<ѻý>Novel Aldosterone Synthase Inhibitor Cuts Albuminuria in Phase II Trialѻý> Trial tested BI 690517 with and without empagliflozin Nov 06, 2023
<ѻý>Heart Injuries Suggest Reconsideration of Holding BP Meds for Surgeryѻý> Pause on ACE inhibitors, ARBs yields more acute hypertension with no prevention of hypotension Nov 06, 2023
<ѻý>Kidney Transplant Rates Stubbornly Resist Systems Intervention in Canadaѻý> Multi-pronged approach to boost living and deceased donor transplant fails in randomized trial Nov 06, 2023
<ѻý>Sparsentan Bests Irbesartan for Preserving Kidney Function in IgA Nephropathyѻý> Proteinuria reduction and slower eGFR decline in 2-year PROTECT trial Nov 05, 2023
<ѻý>ERA and SGLT2 Inhibitor Combo Cuts Albuminuria in Chronic Kidney Diseaseѻý> But ZENITH-CKD trial had to pivot to only using low-dose zibotentan due to fluid retention Nov 05, 2023
<ѻý>Heat and Cardiovascular Death; Time-Restricted Eating or Caloric Restriction in T2Dѻý> Also in TTHealthWatch: managing nasal airway obstruction Nov 04, 2023 podcast
<ѻý>Pharmacist Prescribing for BP Control Makes Economic Senseѻý> Clinical benefits of pharmacist-prescribed antihypertensives known for years Nov 03, 2023
<ѻý>Sparsentan Failed to Preserve Kidney Function Over Time in FSGSѻý> However, more patients on the drug achieved partial remission of proteinuria vs irbesartan Nov 03, 2023
<ѻý>Mid-Stage Win for Novel IgA Nephropathy Drugѻý> APRIL-neutralizing antibody sibeprenlimab reduced proteinuria and stabilized eGFR Nov 02, 2023
<ѻý>Fecal Transplants in Kidney Recipients Reduced Resistant Pathogensѻý> Multidrug resistant organisms replaced by competing antibiotic-susceptible relatives Nov 01, 2023
<ѻý>Year in Review: Type 2 Diabetesѻý> New approvals, guidance on GLP-1s before surgery, and access issues led the news in 2023 Nov 01, 2023
<ѻý>Wegovy and Thyroid Cancer; Maine Shooter's Mental Health; 469 Heat Deathsѻý> Health news and commentary from around the Web gathered by ѻý staff Oct 30, 2023
<ѻý>Tricuspid Valve Replacement Safe, Effective in Pivotal Trialѻý> Outcome data still awaited after positive interim results Oct 27, 2023
<ѻý>Another Study Highlights Metformin's Dementia Protection Propertiesѻý> Association appeared irrespective of HbA1c level Oct 25, 2023
<ѻý>Cruise Line Found Negligent About COVID; Dialysis Machine Recall; MRI Injures Nurseѻý> Health news and commentary from around the Web gathered by ѻý staff Oct 25, 2023
<ѻý>Low-Risk TAVR Converging or Diverging With Surgical Outcomes, Depending on the Valveѻý> Intermediate-term reports from PARTNER 3 and Evolut Low Risk trials Oct 24, 2023
<ѻý>CVS Pulls Phenylephrine Cold Meds; Doc's Murder/Suicide; Red Meat and Diabetesѻý> Health news and commentary from around the Web gathered by ѻý staff Oct 20, 2023
<ѻý>Highly Potent Statin Stands Out for Diabetes, Cataract Risksѻý> Head-to-head comparison of rosuvastatin vs atorvastatin in LODESTAR trial Oct 19, 2023
<ѻý>How to Deprescribe Dialysis After Patients Leave the Hospitalѻý> Acute kidney injury patients should not be left on dialysis longer than necessary Oct 19, 2023
<ѻý>FDA Approves First Phosphate Absorption Inhibitor for CKDѻý> Tenapanor indicated for adults on dialysis who fail on phosphate binders Oct 18, 2023
<ѻý>Antibiotic Combo for Acute Infection Cleared of Kidney Riskѻý> Use of cefepime meanwhile resulted in more neurological dysfunction Oct 16, 2023
<ѻý>'Surprising' Contribution of Pulmonary Hypertension to ARDS Outcomesѻý> Coexisting conditions spell markedly poor clinical course Oct 12, 2023
<ѻý>Modest Risks Come With Moving Fast on HF Drugs After Acute Eventѻý> STRONG-HF analysis details the impact Oct 10, 2023
<ѻý>Risk of Contrast Media Causing Acute Kidney Injury Is Overblown, Study Findsѻý> Despite restrictions on its use, an association with kidney injury hasn't been shown Oct 10, 2023
<ѻý>Time to Recognize Cardiovascular-Kidney-Metabolic Syndrome, AHA Saysѻý> Pooled cohort equations will make way for new CKM risk calculator Oct 09, 2023
<ѻý>Inflammation of the Aorta; Afib in the Hospitalѻý> Also in TTHealthWatch: standards for osteoporosis screening and HbA1c in premenopausal women Oct 07, 2023 podcast
<ѻý>CPAP Turns in Mixed Results for Patients With Diabetic Eye Diseaseѻý> Slower progression of retinal disease, but an increase in microhemorrhages Oct 06, 2023
<ѻý>Smoking-Related Metabolic Changes Partly Drive Type 2 Diabetes Riskѻý> Those with the most metabolic changes, genetic risk had a threefold higher diabetes risk Oct 06, 2023
<ѻý>Faster-Acting Insulin Aspart Safe for Pregnant Women With Diabetesѻý> The faster formulation led to fewer hypoglycemia events versus conventional insulin aspart Oct 06, 2023
<ѻý>Adherence Matters for CVD Secondary Prevention in CPAP Usersѻý> Questionable benefit may hinge on number of hours used Oct 05, 2023
<ѻý>Hybrid Closed-Loop Insulin System for T1D Safe, Effective During Pregnancyѻý> However, no FDA-approved systems have a pregnancy indication yet Oct 05, 2023
<ѻý>Mixed Bag for Early Metformin in Gestational Diabetesѻý> EMERGE trial misses on primary endpoint, but secondary outcomes suggest potential benefit Oct 03, 2023
<ѻý>Adding Tirzepatide to Basal Insulin Cuts HbA1c in Poorly Controlled T2Dѻý> Results with the GIP/GLP-1 receptor agonist were statistically superior to added insulin lispro Oct 03, 2023
<ѻý>Repeat Tests for Inflammation Aid Prognosis After Acute Heart Failureѻý> Mortality predicted by cumulative hsCRP levels over time Oct 02, 2023
<ѻý>FDA OKs Another Injectable for Rare Kidney Disorderѻý> Nedosiran approved for patients ages 9 years and older with primary hyperoxaluria type 1 Oct 02, 2023
<ѻý>FDA Adds Intestinal Blockage Reports to Ozempic Labelingѻý> Joins other approved GLP-1 receptor agonists in noting the potential adverse reaction Sep 28, 2023
<ѻý>Postmenopausal Fracture Risk for SGLT2 Inhibitors Similar to Other Diabetes Drugsѻý> Lower risk compared with DPP-4 inhibitors, and similar risk versus GLP-1 receptor agonists Sep 26, 2023
<ѻý>FDA Approves Another SGLT2 Inhibitor for Treating CKDѻý> Empagliflozin adds indication in adults, regardless of diabetes status Sep 22, 2023